ClinicalTrials.gg
CompletedNCT02528214VENTUREUpdated Oct 1, 2019Results posted

Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma

A Phase 3 interventional study of Dupilumab and Placebo in Asthma, sponsored by Sanofi. Completed at 80 sites in 17 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-10-01.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
11th of 31
210 · median 120
Started
2015
with 1 other
Phase 3
11 of 31
2 open now
Registered
5th of 31
by date
Lead sponsor
15 of 31
Sanofi

Among the 31 studies testing dupilumab in Asthma, this one is the 11th largest by enrollment, is one of 2 that started in 2015, is one of 11 in phase 3, and was the 5th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

Primary Objective:

To evaluate the efficacy of dupilumab, compared with placebo, for reducing the use of maintenance oral corticosteroids (OCS) in participants with severe steroid-dependent asthma.

Secondary Objectives:

  • To evaluate the safety and tolerability of dupilumab.
  • To evaluate the effect of dupilumab in improving participants-reported outcomes.
  • To evaluate dupilumab systemic exposure and the incidence of treatment-emergent antidrug antibodies.
Read the detailed description

The total study duration per participant was up to 46 weeks, consisting of a screening period of 3 to up to 8 weeks (up to 10 weeks for participants who experienced a clinically significant asthma exacerbation during the screening period), a randomized treatment period of up to 24 weeks, and a post-treatment period of 12 weeks.

Participants who completed treatment were considered for eligibility into the long term extension study LTS12551 (NCT02134028).

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult and adolescent (12 years of age or older) participants with a physician diagnosis of asthma for >=12 months, based on the Global Initiative for Asthma (GINA) 2014 guidelines and the following criteria:

  • Participants with severe asthma and a well-documented, regular prescribed treatment of maintenance in the 6 months prior to Visit 1 and using a stable OCS dose (ie, no change of OCS dose) for 4 weeks prior to Visit 1. Participants must be taking 5 to 35 mg/day of prednisone/prednisolone, or the equivalent, at Visit 1 and at the randomization visit. In addition, the participants must agree to switch to study-required prednisone/prednisolone as their OCS and use it per protocol for the duration of the study.
  • Existing treatment with high-dose inhaled corticosteroid (ICS; >500 mcg total daily dose of fluticasone propionate or equivalent) in combination with a second controller (ie, long-acting beta agonist [LABA], leukotriene receptor antagonist [LTRA]) for at least 3 months with a stable dose of ICS for >=1 month prior to Visit 1. In addition, participants requiring a third controller for their asthma are considered eligible for this study, and it should also be used for at least 3 months with a stable dose >= 1 month prior to Visit 1.
  • A (FEV1) \<80% of predicted normal for adults and \<=90% of predicted normal for adolescents at Visit 1.
  • Evidence of asthma as documented by either: reversibility of at least 12% and 200 mL in FEV1 after the administration of 200 to 400 mcg (2 to 4 inhalations of albuterol/salbutamol or levalbuterol/levosalbutamol, or of a nebulized solution of albuterol/salbutamol or levalbuterol/levosalbutamol, if considered as a standard office practice) before randomization or documented in the 12 months prior to Visit 1 OR airway hyperresponsiveness (methacholine: provocative concentration that causes a positive reaction [PC20] of \<8 mg/mL) documented in the 12 months prior to Visit 1.

Exclusion criteria

Exclusion criteria:

  • Participants \<12 years of age or the minimum legal age for adolescents in the country of the investigative site, whichever is higher (for those countries where local regulations permit enrollment of adults only, participant recruitment will be restricted to those who were >=18 years of age).
  • Participants who weighed \<30.0 kg.
  • (COPD) or other lung diseases (eg, idiopathic pulmonary fibrosis, Churg-Strauss Syndrome, allergic bronchopulmonary aspergillosis, cystic fibrosis) which may impair lung function.
  • Clinical evidence or imaging (eg, chest X-ray, computed tomography, magnetic resonance imaging) within 12 months of Visit 1 with findings of lung disease(s) other than asthma, as per local standard of care.
  • A participant who experiences a deterioration of asthma that results in emergency treatment or hospitalization within 4 weeks of Screening Visit 1.
  • A participant who requires 12 puffs or more of rescue medication on any 1 day in the week prior to Visit 1.
  • A participant who has experienced an upper or lower respiratory tract infection within the 4 weeks prior to screening.
  • Current smoker or cessation of smoking within 6 months prior to Visit 1.
  • Previous smoker with a smoking history >10 pack-years.
  • Comorbid disease that might interfere with the evaluation of the medicinal product.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
210 participants (actual)

Study arms

  • Placebo comparator
    Placebo q2w

    2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.

    Drug: Placebo · Drug: Oral corticosteroid therapy (prednisone/prednisolone) · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol

  • Experimental
    Dupilumab 300 mg q2w

    2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.

    Drug: Dupilumab · Drug: Oral corticosteroid therapy (prednisone/prednisolone) · Drug: Inhaled corticosteroid (ICS) therapy · Drug: Albuterol/Salbutamol · Drug: Levalbuterol/Levosalbutamol

Interventions

  • Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

    Also known as: REGN668, SAR231893

  • DrugPlacebo

    Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.

  • DrugOral corticosteroid therapy (prednisone/prednisolone)

    Oral administration.

  • DrugInhaled corticosteroid (ICS) therapy

    Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).

  • DrugAlbuterol/Salbutamol

    Drug page: Albuterol

    Oral inhalation as needed.

  • DrugLevalbuterol/Levosalbutamol

    Drug page: Levalbuterol

    Oral inhalation as needed.

06

What researchers measure

Primary outcomes

  1. Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control

    Percentage reduction of OCS dose was calculated as (optimized OCS dose \[mg/day\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100. Result is presented as Least Squares Mean (Standard Error) percentage reduction from baseline derived from ANCOVA model with missing data multiply imputed.

    Time frame: Baseline, Week 24

  2. Supplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control

    The Primary Outcome Measure (Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control) is summarized above, as LS Mean (SE). Table below provides a supplementary presentation of the Primary Outcome Measure data; result is presented as median (inter-quartile range). Percentage reduction of OCS dose was calculated as (optimized OCS dose \[mg/day\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of Participants Achieving >= 50% Reduction in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control

    Participants were classified according to the binary status of whether or not the 50% OCS dose reduction criterion was achieved at week 24.

    Time frame: Week 24

  2. Percentage of Participants Achieving a Reduction in Oral Corticosteroids Dose to <5 mg/Day at Week 24 While Maintaining Asthma Control

    Participants were classified according to the binary status of whether or not the reduction of OCS dose to \<5 mg/day was achieved at Week 24.

    Time frame: Week 24

  3. Percentage of Participants Achieving Maximum Possible Reduction in Oral Corticosteroids Dose Per Protocol at Week 24 While Maintaining Asthma Control

    For all participants except those with baseline OCS dose at 35 mg/day, the maximum possible reduction corresponds to reduction to 0 mg/day (no longer requiring OCS). For participants starting with 35 mg/day at baseline, the maximum possible reduction is 32.5 mg/day (i.e. minimum dose per protocol is 2.5 mg).

    Time frame: Week 24

  4. Percentage of Participants Who No Longer Required Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control

    Participants were classified according to the binary status of whether or not the participant still required OCS at Week 24 while maintaining asthma control.

    Time frame: Week 24

  5. Absolute Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control

    Absolute reduction was calculated by subtracting Week 24 value from baseline value.

    Time frame: Baseline and Week 24

Other outcomes

  1. Annualized Rate of Severe Exacerbation Events During The 24-Week Treatment Period

    A severe asthma exacerbation event was defined as a deterioration of asthma during the 24-week treatment period requiring: use of systemic corticosteroids for \>=3 days (at least double the dose currently used); and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring intervention with a systemic corticosteroid treatment. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

    Time frame: Baseline to Week 24

  2. Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Weeks 12 and 24

    FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

    Time frame: Baseline, Week 12 and Week 24

  3. Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Score at Weeks 2, 4, 8, 12, 16, 20, and 24

    The ACQ-5 has 5 questions, reflecting top-scoring 5 asthma symptoms: woken at night by symptoms, wake in mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during previous week and to respond to each of 5 symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.

    Time frame: Baseline and at Weeks 2, 4, 8, 12, 16, 20, and 24

  4. Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12 and Week 24

    AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that were most important to participants with asthma. AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.

    Time frame: Baseline, Week 12 and Week 24

  5. Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Week 12 and Week 24

    EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).

    Time frame: Baseline, Week 12 and Week 24

  6. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Week 12 and Week 24

    The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. And, the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.

    Time frame: Baseline, Week 12 and Week 24

  7. Change From Baseline in Sino Nasal Outcome Test-22 (SNOT-22) Global Score at Week 12 and Week 24

    The SNOT-22 is a validated measure of health related quality of life in sino nasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.

    Time frame: Baseline, Week 12 and Week 24

07

Results

Posted Oct 23, 2018

Participant flow

The study was conducted at 68 centers in 17 countries. A total of 390 participants were screened between October 2015 \& April 2017, of which,210 were randomized \& treated. 180 participants were screen failures mainly due to exclusion criteria met \& inclusion criteria not met. Assignment was done by Interactive Voice/Web Response System(IVRS/IWRS).

Participant flow — Overall Study
MilestonePlacebo q2wDupilumab 300 mg q2w
Started107103
Treated107103
Completed107100
Not completed03
Withdrew: Protocol violation01
Withdrew: Adverse event01
Withdrew: Other than specified above01

Outcome measures

PrimaryPercentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control

Percentage reduction of OCS dose was calculated as (optimized OCS dose \[mg/day\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100. Result is presented as Least Squares Mean (Standard Error) percentage reduction from baseline derived from ANCOVA model with missing data multiply imputed.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percentage reduction from baseline
Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control
Percentage reduction from baselinePlacebo q2wDupilumab 300 mg q2w
Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control41.85 ± 4.5770.09 ± 4.90
Statistical analysis
  • Placebo q2w vs Dupilumab 300 mg q2w · ANCOVA · p = < 0.0001 (Threshold for significance at two-sided 0.05 level.) · Least square (ls) mean difference: 28.24 · 95% CI 15.81 to 40.67LS mean difference represents reduction difference i.e. dupilumab - placebo.
PrimarySupplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control

The Primary Outcome Measure (Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control) is summarized above, as LS Mean (SE). Table below provides a supplementary presentation of the Primary Outcome Measure data; result is presented as median (inter-quartile range). Percentage reduction of OCS dose was calculated as (optimized OCS dose \[mg/day\] at baseline - final OCS dose at Week 24)/optimized OCS dose at baseline x 100.

Time frame:
Baseline, Week 24
Reported as:
Median · percentage reduction from baseline
Supplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
percentage reduction from baselinePlacebo q2wDupilumab 300 mg q2w
Supplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control50.0 (0 to 100.0)100.0 (62.5 to 100.0)
SecondaryPercentage of Participants Achieving >= 50% Reduction in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control

Participants were classified according to the binary status of whether or not the 50% OCS dose reduction criterion was achieved at week 24.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving >= 50% Reduction in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
percentage of participantsPlacebo q2wDupilumab 300 mg q2w
Percentage of Participants Achieving >= 50% Reduction in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control53.379.6
Statistical analysis
  • Placebo q2w vs Dupilumab 300 mg q2w · Regression, Logistic · p = < 0.0001 (Threshold for significance at 0.05.) · Odds ratio (or): 3.98 · 95% CI 2.06 to 7.67Dupilumab 300 mg q2w v Placebo q2w
SecondaryPercentage of Participants Achieving a Reduction in Oral Corticosteroids Dose to <5 mg/Day at Week 24 While Maintaining Asthma Control

Participants were classified according to the binary status of whether or not the reduction of OCS dose to \<5 mg/day was achieved at Week 24.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Reduction in Oral Corticosteroids Dose to <5 mg/Day at Week 24 While Maintaining Asthma Control
percentage of participantsPlacebo q2wDupilumab 300 mg q2w
Percentage of Participants Achieving a Reduction in Oral Corticosteroids Dose to <5 mg/Day at Week 24 While Maintaining Asthma Control37.471.8
Statistical analysis
  • Placebo q2w vs Dupilumab 300 mg q2w · Regression, Logistic · p = < 0.0001 (Threshold for significance at 0.05.) · Odds ratio (or): 4.48 · 95% CI 2.39 to 8.39Dupilumab 300 mg q2w v Placebo q2w
SecondaryPercentage of Participants Achieving Maximum Possible Reduction in Oral Corticosteroids Dose Per Protocol at Week 24 While Maintaining Asthma Control

For all participants except those with baseline OCS dose at 35 mg/day, the maximum possible reduction corresponds to reduction to 0 mg/day (no longer requiring OCS). For participants starting with 35 mg/day at baseline, the maximum possible reduction is 32.5 mg/day (i.e. minimum dose per protocol is 2.5 mg).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Maximum Possible Reduction in Oral Corticosteroids Dose Per Protocol at Week 24 While Maintaining Asthma Control
percentage of participantsPlacebo q2wDupilumab 300 mg q2w
Percentage of Participants Achieving Maximum Possible Reduction in Oral Corticosteroids Dose Per Protocol at Week 24 While Maintaining Asthma Control29.952.4
Statistical analysis
  • Placebo q2w vs Dupilumab 300 mg q2w · Regression, Logistic · p = 0.0024 (Threshold for significance at 0.05.) · Odds ratio (or): 2.57 · 95% CI 1.4 to 4.73Dupilumab 300 mg q2w v Placebo q2w
SecondaryPercentage of Participants Who No Longer Required Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control

Participants were classified according to the binary status of whether or not the participant still required OCS at Week 24 while maintaining asthma control.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who No Longer Required Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
percentage of participantsPlacebo q2wDupilumab 300 mg q2w
Percentage of Participants Who No Longer Required Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control29.252.4
Statistical analysis
  • Placebo q2w vs Dupilumab 300 mg q2w · Regression, Logistic · p = 0.0015 (Threshold for significance at 0.05.) · Odds ratio (or): 2.74 · 95% CI 1.47 to 5.1Dupilumab 300 mg q2w v Placebo q2w
SecondaryAbsolute Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control

Absolute reduction was calculated by subtracting Week 24 value from baseline value.

Time frame:
Baseline and Week 24
Reported as:
Mean · mg/day
Absolute Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control
mg/dayPlacebo q2wDupilumab 300 mg q2w
Baseline11.75 ± 6.3110.75 ± 5.90
Week 246.32 ± 6.753.13 ± 5.44
Absolute reduction at Week 245.45 ± 6.807.66 ± 6.10
Other pre-specifiedAnnualized Rate of Severe Exacerbation Events During The 24-Week Treatment Period

A severe asthma exacerbation event was defined as a deterioration of asthma during the 24-week treatment period requiring: use of systemic corticosteroids for \>=3 days (at least double the dose currently used); and/or hospitalization related to asthma symptoms or emergency room visit because of asthma requiring intervention with a systemic corticosteroid treatment. Annualized event rate was the total number of exacerbations that occurred during the treatment period divided by the total number of participant-years treated.

Time frame:
Baseline to Week 24
Reported as:
Number · Exacerbation per participant-year
Annualized Rate of Severe Exacerbation Events During The 24-Week Treatment Period
Exacerbation per participant-yearPlacebo q2wDupilumab 300 mg q2w
Annualized Rate of Severe Exacerbation Events During The 24-Week Treatment Period1.597 (1.248 to 2.043)0.649 (0.442 to 0.955)
Other pre-specifiedChange From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Weeks 12 and 24

FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · liter
Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Weeks 12 and 24
literPlacebo q2wDupilumab 300 mg q2w
Baseline1.63 ± 0.611.53 ± 0.53
Week 121.68 ± 0.611.82 ± 0.63
Change at Week 120.06 ± 0.500.29 ± 0.43
Week 241.63 ± 0.651.84 ± 0.60
Change at Week 240.00 ± 0.510.29 ± 0.46
Other pre-specifiedChange From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Score at Weeks 2, 4, 8, 12, 16, 20, and 24

The ACQ-5 has 5 questions, reflecting top-scoring 5 asthma symptoms: woken at night by symptoms, wake in mornings with symptoms, limitation of daily activities, shortness of breath and wheeze. Participants were asked to recall how their asthma had been during previous week and to respond to each of 5 symptom questions on a 7-point scale ranged from 0 (no impairment) to 6 (maximum impairment). ACQ-5 total score was mean of scores of all 5 questions and, therefore, ranged from 0 (totally controlled) to 6 (severely uncontrolled). Higher score indicated lower asthma control.

Time frame:
Baseline and at Weeks 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Score at Weeks 2, 4, 8, 12, 16, 20, and 24
score on a scalePlacebo q2wDupilumab 300 mg q2w
Change at Week 2-0.18 ± 0.67-0.49 ± 0.86
Change at Week 4-0.36 ± 0.81-0.61 ± 1.01
Change at Week 8-0.39 ± 1.13-0.68 ± 1.06
Change at Week 12-0.54 ± 1.17-0.92 ± 1.09
Change at Week 16-0.57 ± 1.05-0.87 ± 1.18
Change at Week 20-0.53 ± 1.09-0.83 ± 1.19
Change at Week 24-0.57 ± 1.19-0.94 ± 1.22
Other pre-specifiedChange From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12 and Week 24

AQLQ is a disease-specific, self-administered quality of life questionnaire designed to measure functional impairments that were most important to participants with asthma. AQLQ comprised of 32 items in 4 domains: symptoms (12 items), activity limitation (11 items), emotional function (5 items), environmental stimuli (4 items). Each item was scored on a 7-point likert scale (1=maximal impairment, 7=no impairment). The 32 items of the questionnaire were averaged to produce one overall quality of life score ranging from 1 (severely impaired) to 7 (not impaired at all). Higher scores indicate better quality of life.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12 and Week 24
score on a scalePlacebo q2wDupilumab 300 mg q2w
Change at Week 120.56 ± 1.080.78 ± 1.09
Change at Week 240.56 ± 0.970.94 ± 1.17
Other pre-specifiedChange From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Week 12 and Week 24

EQ-5D-5L is a standardized health-related quality of life questionnaire developed by EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state. EQ-5D-5L-VAS records participant's self-rated health on a vertical VAS that allows them to indicate their health state that can range from 0 (worst imaginable) to 100 (best imaginable).

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Median · score on a scale
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Week 12 and Week 24
score on a scalePlacebo q2wDupilumab 300 mg q2w
Single Index: Change at Week 120.04 ± 0.200.03 ± 0.17
Single Index: Change at Week 240.05 ± 0.180.05 ± 0.18
VAS Score: Change at Week 125.99 ± 16.859.34 ± 18.20
VAS Score: Change at Week 244.16 ± 16.7411.06 ± 17.60
Other pre-specifiedChange From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Week 12 and Week 24

The HADS is a general scale to detect states of anxiety and depression already used and validated in asthma, which includes HADS-A and HADS-D subscales. The instrument is comprised of 14 items: 7 related to anxiety (HADS-A) and 7 to depression (HADS-D). Each item on the questionnaire is scored from 0-3. And, the total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher anxiety/depression complains.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Week 12 and Week 24
score on a scalePlacebo q2wDupilumab 300 mg q2w
Change at Week 12-0.75 ± 5.50-2.13 ± 5.32
Change at Week 24-0.99 ± 5.36-2.53 ± 5.98
Other pre-specifiedChange From Baseline in Sino Nasal Outcome Test-22 (SNOT-22) Global Score at Week 12 and Week 24

The SNOT-22 is a validated measure of health related quality of life in sino nasal disease. It is a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease), lower scores represent better health related quality of life.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Sino Nasal Outcome Test-22 (SNOT-22) Global Score at Week 12 and Week 24
score on a scalePlacebo q2wDupilumab 300 mg q2w
Change at Week 12-3.79 ± 21.34-12.45 ± 17.10
Change at Week 24-2.46 ± 19.11-14.56 ± 15.89

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 36) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo q2w0/107 (0%)6/107 (5.6%)30/107 (28%)
Dupilumab 300mg q2w0/103 (0%)9/103 (8.7%)29/103 (28.2%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlacebo q2wDupilumab 300mg q2w
AsthmaRespiratory, thoracic and mediastinal disorders3/1073/103
EosinophiliaBlood and lymphatic system disorders0/1072/103
PneumoniaInfections and infestations0/1071/103
Respiratory tract infectionInfections and infestations0/1071/103
ChylothoraxRespiratory, thoracic and mediastinal disorders0/1071/103
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/1071/103
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1071/103
Pulmonary massRespiratory, thoracic and mediastinal disorders0/1071/103
Acetabulum fractureInjury, poisoning and procedural complications0/1071/103
Foreign body aspirationInjury, poisoning and procedural complications0/1071/103
Most frequent other events
Most frequent other events
EventPlacebo q2wDupilumab 300mg q2w
Viral upper respiratory tract infectionInfections and infestations19/1079/103
BronchitisInfections and infestations6/1077/103
SinusitisInfections and infestations4/1077/103
Eosinophil count increasedInvestigations0/1077/103
InfluenzaInfections and infestations6/1073/103

Baseline characteristics

Baseline population included all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo q2wDupilumab 300 mg q2wTotal
Mean50.7 ± 12.851.9 ± 12.551.3 ± 12.6
Age, Customized
Age, Customized(Participants)Placebo q2wDupilumab 300 mg q2wTotal
<18 years213
Between 18 and 64 years8891179
>=65 years171128
Sex: Female, Male
Sex: Female, Male(Participants)Placebo q2wDupilumab 300 mg q2wTotal
Female6562127
Male424183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo q2wDupilumab 300 mg q2wTotal
Hispanic or Latino222345
Not Hispanic or Latino8580165
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo q2wDupilumab 300 mg q2wTotal
Caucasian/White10097197
Black/of African descent145
Asian/Oriental202
American Indian or Alaska Native202
Native Hawaiian or Other Pacific Islander011
Other213
Baseline Blood Eosinophil Count
Baseline Blood Eosinophil Count(Participants)Placebo q2wDupilumab 300 mg q2wTotal
<0.15 Giga/L382260
>=0.15 - <0.3 Giga/L283361
>=0.3 Giga/L414889
Baseline Optimized Daily OCS Dose
Baseline Optimized Daily OCS Dose(mg/day)Placebo q2wDupilumab 300 mg q2wTotal
Mean11.75 ± 6.3110.75 ± 5.911.26 ± 6.12
Daily OCS Dose at Visit 1 (i.e. preoptimization)
Daily OCS Dose at Visit 1 (i.e. preoptimization)(mg/day)Placebo q2wDupilumab 300 mg q2wTotal
Mean11.83 ± 6.0211.79 ± 6.411.81 ± 6.20
08

Study locations

80 sites
  • Investigational Site Number 840022
    Los Angeles, California 90048, United States
  • Investigational Site Number 840014
    Rolling Hills Estates, California 90274, United States
  • Investigational Site Number 840002
    Saint Louis, Missouri 63110, United States
  • Investigational Site Number 840010
    Pittsburgh, Pennsylvania 15213, United States
  • Investigational Site Number 840062
    Amarillo, Texas 79106, United States
  • Investigational Site Number 840070
    McKinney, Texas 75069, United States
  • Investigational Site Number 840128
    McKinney, Texas 75071, United States
  • Investigational Site Number 840118
    Plano, Texas 75093, United States
  • Investigational Site Number 032003
    Buenos Aires, C1121ABE, Argentina
  • Investigational Site Number 032001
    Caba, C1425BEN, Argentina
  • Investigational Site Number 032091
    Caba, C1426ABP, Argentina
  • Investigational Site Number 056002
    Brussels, 1020, Belgium
  • Investigational Site Number 056003
    Gent, 9000, Belgium
  • Investigational Site Number 056001
    Leuven, 3000, Belgium
  • Investigational Site Number 076011
    Sao Paulo, 04020-041, Brazil
  • Investigational Site Number 076002
    Sorocaba, 18040-425, Brazil
  • Investigational Site Number 076013
    São Bernardo Do Campo, 09780-000, Brazil
  • Investigational Site Number 124009
    Calgary, T2N 4Z6, Canada
  • Investigational Site Number 124016
    Hamilton, L8N 4A6, Canada
  • Investigational Site Number 124003
    Mississauga, L5A 3V4, Canada
  • Investigational Site Number 124013
    Ottawa, K1G 6C6, Canada
  • Investigational Site Number 124002
    Toronto, M5T 3A9, Canada
  • Investigational Site Number 124017
    Vancouver, V6Z 1Y6, Canada
  • Investigational Site Number 152007
    Quillota, 2260877, Chile
  • Investigational Site Number 152005
    Santiago, 7500692, Chile
  • Investigational Site Number 152008
    Talca, 3460001, Chile
  • Investigational Site Number 170001
    Bogota, 110121, Colombia
  • Investigational Site Number 170006
    Bogota, Colombia
  • Investigational Site Number 348301
    Balassagyarmat, 2660, Hungary
  • Investigational Site Number 348303
    Edelény, 3780, Hungary
  • Investigational Site Number 376003
    Haifa, 34362, Israel
  • Investigational Site Number 376001
    Kfar Saba, 44281, Israel
  • Investigational Site Number 376005
    Petah-Tikva, 49100, Israel
  • Investigational Site Number 376002
    Rehovot, 76100, Israel
  • Investigational Site Number 376004
    Tel Hashomer, 52621, Israel
  • Investigational Site Number 380005
    Catania, 95123, Italy
  • Investigational Site Number 380002
    Genova, 16132, Italy
  • Investigational Site Number 380008
    Napoli, 80131, Italy
  • Investigational Site Number 380009
    Palermo, 90146, Italy
  • Investigational Site Number 380001
    Pisa, 56124, Italy
  • Investigational Site Number 380003
    Reggio Emilia, 42123, Italy
  • Investigational Site Number 484016
    Acapulco, 39670, Mexico
  • Investigational Site Number 484013
    Chihuahua, 31020, Mexico
  • Investigational Site Number 484001
    Guadalajara, 44100, Mexico
  • Investigational Site Number 484002
    Mexico, Df, 06726, Mexico
  • Investigational Site Number 484003
    Monterrey, 64460, Mexico
  • Investigational Site Number 528001
    Arnhem, 6815 AD, Netherlands
  • Investigational Site Number 528002
    Dordrecht, 3318 AT, Netherlands
  • Investigational Site Number 616006
    Bialystok, 15-010, Poland
  • Investigational Site Number 616097
    Krakow, 31-159, Poland
  • Investigational Site Number 616001
    Lodz, 90-141, Poland
  • Investigational Site Number 616010
    Warszawa, 04-141, Poland
  • Investigational Site Number 616011
    Znin, 88-400, Poland
  • Investigational Site Number 642104
    Bucharest, 011461, Romania
  • Investigational Site Number 642103
    Bucharest, 050159, Romania
  • Investigational Site Number 642102
    Cluj-Napoca, 400162, Romania
  • Investigational Site Number 642107
    Cluj-Napoca, 400371, Romania
  • Investigational Site Number 642108
    Cluj-Napoca, 400371, Romania
  • Investigational Site Number 642105
    Timisoara, 300310, Romania
  • Investigational Site Number 642106
    Timisoara, 300310, Romania
  • Investigational Site Number 643006
    Moscow, 105077, Russian Federation
  • Investigational Site Number 643007
    Moscow, 117574, Russian Federation
  • Investigational Site Number 643011
    Saint-Petersburg, 194356, Russian Federation
  • Investigational Site Number 643099
    St-Petersburg, 193231, Russian Federation
  • Investigational Site Number 643009
    St-Petersburg, 197022, Russian Federation
  • Investigational Site Number 724014
    Barcelona, 08023, Spain
  • Investigational Site Number 724002
    Barcelona, 08035, Spain
  • Investigational Site Number 724013
    Madrid, 28942, Spain
  • Investigational Site Number 724006
    Pozuelo De Alarcón, 28223, Spain
  • Investigational Site Number 724007
    Sant Boi De Llobregat, 08830, Spain
  • Investigational Site Number 724096
    Santiago De Compostela, 15706, Spain
  • Investigational Site Number 804007
    Chernivtsi, 58001, Ukraine
  • Investigational Site Number 804004
    Ivano-Frankivsk, 76018, Ukraine
  • Investigational Site Number 804009
    Ivano-Frankivsk, 76018, Ukraine
  • Investigational Site Number 804001
    Kharkiv, 61124, Ukraine
  • Investigational Site Number 804003
    Kyiv, 03680, Ukraine
  • Investigational Site Number 804011
    Kyiv, 03680, Ukraine
  • Investigational Site Number 804006
    Odessa, 65025, Ukraine
  • Investigational Site Number 804002
    Poltava, 36038, Ukraine
  • Investigational Site Number 804019
    Vinnytsya, 21001, Ukraine
09

References and documents

Publications

  • Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A, Chao J, Staudinger H, Pirozzi G, Antoni C, Amin N, Ruddy M, Akinlade B, Graham NMH, Stahl N, Yancopoulos GD, Teper A. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018 Jun 28;378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21. PubMed 29782224 ↗
  • Lugogo N, Mohan A. Are We Poised to Change the Trajectory of Maintenance Oral Corticosteroid Use in Severe Asthma in the Age of Biologics? Chest. 2022 Jul;162(1):4-5. doi: 10.1016/j.chest.2022.04.004. No abstract available. PubMed 35809937 ↗
  • Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28. PubMed 35636689 ↗
  • Domingo C, Maspero JF, Castro M, Hanania NA, Ford LB, Halpin DMG, Jackson DJ, Daizadeh N, Djandji M, Mitchell CP, Crikelair N, Jacob-Nara JA, Deniz Y, Rowe PJ, Ortiz B. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. J Allergy Clin Immunol Pract. 2022 Jul;10(7):1835-1843. doi: 10.1016/j.jaip.2022.03.020. Epub 2022 Apr 8. PubMed 35398549 ↗
  • Sher LD, Wechsler ME, Rabe KF, Maspero JF, Daizadeh N, Mao X, Ortiz B, Mannent LP, Laws E, Ruddy M, Pandit-Abid N, Jacob-Nara JA, Gall R, Rowe PJ, Deniz Y, Lederer DJ, Hardin M. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial. Chest. 2022 Jul;162(1):46-55. doi: 10.1016/j.chest.2022.01.071. Epub 2022 Feb 22. PubMed 35217003 ↗
  • Tohda Y, Matsumoto H, Miyata M, Taguchi Y, Ueyama M, Joulain F, Arakawa I. Cost-effectiveness analysis of dupilumab among patients with oral corticosteroid-dependent uncontrolled severe asthma in Japan. J Asthma. 2022 Nov;59(11):2162-2173. doi: 10.1080/02770903.2021.1996596. Epub 2021 Dec 8. PubMed 34752208 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Sep 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2015
First posted
Aug 19, 2015
Start
Oct 15, 2015
Primary completionActual
Sep 20, 2017
CompletionActual
Nov 13, 2017
Results first posted
Oct 23, 2018
Last update
Oct 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02528214
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 19, 2015
Start date
Oct 15, 2015
Primary completion
Sep 20, 2017
Completion
Nov 13, 2017
Results posted
Oct 23, 2018
Last update
Oct 1, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion